BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
AstraZeneca
Cantor Fitzgerald
Teva
Baxter
Colorcon
Fuji
McKesson
Express Scripts
Accenture

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,188,146

« Back to Dashboard

Which drugs does patent 8,188,146 protect, and when does it expire?

Patent 8,188,146 protects VASCEPA and is included in one NDA.

This patent has thirty-eight patent family members in thirty-four countries.
Summary for Patent: 8,188,146
Title:Highly purified ethyl EPA and other EPA derivatives
Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
Inventor(s): Peet; Malcolm (Sheffield, GB), Vaddadi; Krishna S. (Melbourne, AU)
Assignee: Amarin Corporation Plc. (Dublin, IE)
Application Number:12/052,598
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,188,146

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,188,146

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9901809.5Jan 27, 1999

Non-Orange Book US Patents Family Members for Patent 8,188,146

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,384,077 Highly purified EPA for treatment of schizophrenia and related disorders ➤ Subscribe
6,689,812 Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders ➤ Subscribe
7,119,118 Highly purified ethyl EPA and other EPA derivatives for treatment of huntington's disease ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,188,146

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 76405 ➤ Subscribe
Taiwan I228041 ➤ Subscribe
Turkey 200504156 ➤ Subscribe
Turkey 200102170 ➤ Subscribe
Slovakia 10392001 ➤ Subscribe
Slovenia 1148873 ➤ Subscribe
Russian Federation 2260423 ➤ Subscribe
Serbia 50133 ➤ Subscribe
Yugoslavia 54201 ➤ Subscribe
Portugal 1148873 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Cerilliant
Julphar
Farmers Insurance
QuintilesIMS
Harvard Business School
Healthtrust
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot